Cargando…

Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea

Combination therapy with interferon alpha (IFN-α) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-α and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jie-Hyun, Han, Kwang-Hyub, Lee, Kwan Sik, Park, Young Nyun, Ahn, Sang Hoon, Chon, Chae Yoon, Moon, Young Myoung
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687818/
https://www.ncbi.nlm.nih.gov/pubmed/17191307
http://dx.doi.org/10.3349/ymj.2006.47.6.793
_version_ 1782167598927970304
author Kim, Jie-Hyun
Han, Kwang-Hyub
Lee, Kwan Sik
Park, Young Nyun
Ahn, Sang Hoon
Chon, Chae Yoon
Moon, Young Myoung
author_facet Kim, Jie-Hyun
Han, Kwang-Hyub
Lee, Kwan Sik
Park, Young Nyun
Ahn, Sang Hoon
Chon, Chae Yoon
Moon, Young Myoung
author_sort Kim, Jie-Hyun
collection PubMed
description Combination therapy with interferon alpha (IFN-α) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-α and ribavirin for chronic hepatitis C in Koreans. One hundred thirty-eight patients with chronic hepatitis C who received this combination therapy between 1995 and 2003 were analyzed retrospectively. All patients were treated with IFN-α 3-6 million units three times weekly in combination with 900-1200 mg/day of ribavirin for 24 weeks. The overall SVR rate was 41.3%. Patients were followed up for a median of 41 months (range, 12-105 months) after completion of therapy. In all of the SVR patients (57 patients), SVR was conserved during the follow-up period. None of the patients progressed to decompensated liver disease or hepatocellular carcinoma (HCC). However, 5 of the 81 non-SVR patients (6.2%) progressed to decompensated liver disease or HCC. In conclusion, combination therapy with IFN-α and ribavirin shows good long-term efficacy in patients with chronic hepatitis C in Korea, one of the highest endemic areas of hepatitis B virus (HBV) infection.
format Text
id pubmed-2687818
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-26878182009-06-04 Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea Kim, Jie-Hyun Han, Kwang-Hyub Lee, Kwan Sik Park, Young Nyun Ahn, Sang Hoon Chon, Chae Yoon Moon, Young Myoung Yonsei Med J Original Article Combination therapy with interferon alpha (IFN-α) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-α and ribavirin for chronic hepatitis C in Koreans. One hundred thirty-eight patients with chronic hepatitis C who received this combination therapy between 1995 and 2003 were analyzed retrospectively. All patients were treated with IFN-α 3-6 million units three times weekly in combination with 900-1200 mg/day of ribavirin for 24 weeks. The overall SVR rate was 41.3%. Patients were followed up for a median of 41 months (range, 12-105 months) after completion of therapy. In all of the SVR patients (57 patients), SVR was conserved during the follow-up period. None of the patients progressed to decompensated liver disease or hepatocellular carcinoma (HCC). However, 5 of the 81 non-SVR patients (6.2%) progressed to decompensated liver disease or HCC. In conclusion, combination therapy with IFN-α and ribavirin shows good long-term efficacy in patients with chronic hepatitis C in Korea, one of the highest endemic areas of hepatitis B virus (HBV) infection. Yonsei University College of Medicine 2006-12-31 2006-12-31 /pmc/articles/PMC2687818/ /pubmed/17191307 http://dx.doi.org/10.3349/ymj.2006.47.6.793 Text en Copyright © 2006 The Yonsei University College of Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Jie-Hyun
Han, Kwang-Hyub
Lee, Kwan Sik
Park, Young Nyun
Ahn, Sang Hoon
Chon, Chae Yoon
Moon, Young Myoung
Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
title Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
title_full Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
title_fullStr Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
title_full_unstemmed Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
title_short Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
title_sort efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis c in korea
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687818/
https://www.ncbi.nlm.nih.gov/pubmed/17191307
http://dx.doi.org/10.3349/ymj.2006.47.6.793
work_keys_str_mv AT kimjiehyun efficacyandlongtermfollowupofcombinationtherapywithinterferonalphaandribavirinforchronichepatitiscinkorea
AT hankwanghyub efficacyandlongtermfollowupofcombinationtherapywithinterferonalphaandribavirinforchronichepatitiscinkorea
AT leekwansik efficacyandlongtermfollowupofcombinationtherapywithinterferonalphaandribavirinforchronichepatitiscinkorea
AT parkyoungnyun efficacyandlongtermfollowupofcombinationtherapywithinterferonalphaandribavirinforchronichepatitiscinkorea
AT ahnsanghoon efficacyandlongtermfollowupofcombinationtherapywithinterferonalphaandribavirinforchronichepatitiscinkorea
AT chonchaeyoon efficacyandlongtermfollowupofcombinationtherapywithinterferonalphaandribavirinforchronichepatitiscinkorea
AT moonyoungmyoung efficacyandlongtermfollowupofcombinationtherapywithinterferonalphaandribavirinforchronichepatitiscinkorea